Deregulation of interleukin-6 (IL-6) expression caused the synthesis and release of many inflammatory mediators. It is involved in chronic inflammation, autoimmune diseases, and malignancy. *Stephania tetrandra* S. Moore is a Chinese medicinal herb which has been used traditionally as a remedy for neuralgia and arthritis in China. To investigate the anti-inflammatory effects of *S. tetrandra* S. Moore in vitro and in vivo, its effects on the production of IL-6 and inflammatory mediators were analysed. When human monocytes/macrophages stimulated with silica were treated with 0.1–10 μg/ml *S. tetrandra* S. Moore, the production of IL-6 was inhibited up to 50%. At these concentrations, it had no cytotoxicity effect on these cells. It also suppressed the production of IL-6 by alveolar macrophages stimulated with silica. In addition, it inhibited the release of superoxide anion and hydrogen peroxide from human monocytes/macrophages. To assess the anti-fibrosis effects of *S. tetrandra* S. Moore, its effects on in vitro experimental inflammatory models were evaluated. In the experimental silicosis model, IL-6 activities in the sera and in the culture supernatants of pulmonary fibroblasts were also inhibited by it. In vitro and in vivo treatment of *S. tetrandra* S. Moore reduced collagen production by rat lung fibroblasts and lung tissue. Also, *S. tetrandra* S. Moore reduced the levels of serum GOT and GPT in the rat cirrhosis model induced by CCL4, and it was effective in reducing hepatic fibrosis and nodular formation. Taken together, these data indicate that it has a potent anti-inflammatory and anti-fibrosis effect by reducing IL-6 production.

**Key words:** Anti-fibrosis, Anti-inflammation, IL-6 production, *Stephania tetrandra*

---

**Introduction**

Inflammation is initiated by the infiltration of inflammatory, immune and mesenchymal cells into the inflamed sites. Monocytes/macrophages involved in the influx of these cells into the inflamed site produce soluble mediators. Once these cells have entered the inflammatory sites, they begin to proliferate and initiate the synthesizing of inflammatory and fibrogenic factors such as collagen. The repair of tissue injury results in replacement of the original tissue by collagen. This collagen production not only serves to repair the damaged tissue, but may also cause damage to the organ.

Silicosis is an occupational lung disease resulting from the inhalation of silica dust which causes chronic inflammation and progressive pulmonary fibrosis. Inhaled silica particles are first ingested by alveolar monocytes/macrophages, which then release oxygen free radicals and lysosomal enzymes which damage lung tissue. They also release pro-inflammatory cytokines which recruit more inflammatory cells to secrete these fibrogenic mediators inducing the proliferation of fibroblasts and collagen synthesis. Hepatic fibrosis is one of the chronic inflammatory liver diseases. It is a complex process that involves the deposition of extracellular matrix components, activation of cells capable of producing inflammatory mediators, cytokines, and tissue remodeling. Unbalanced production of pro-inflammatory cytokines and inflammatory mediators has been reported in chronic liver diseases. In cirrhotic liver, levels of IL-1, TNF, and IL-6 are increased. TGF-β is also involved in collagen synthesis and chronic liver diseases.

As is well known, IL-6 is a regulatory factor...
Stephanatetrandrasuppressed IL-6 production and inflammation which participates in the growth, differentiation and activation of cells. It is produced and secreted by various organ cells, and plays an important role in defensive mechanisms of the human body. IL-6, first discovered in the culture supernatants of monocytes, has been reported to induce the production of antibodies by B cells. Since the successful cloning of the cDNA of IL-6, IL-6 has been reported to serve as a growth factor for B cell hybridoma and plasmacytoma, and as a factor participating in haematopoiesis. Further, IL-6 has been reported to have the functions of stimulating the activation and growth of T cells; inducing the acute phase response of liver cells; regulating cell differentiation in the nervous system; stimulating the growth of keratinocytes; regulating bone metabolism; stimulating the growth of kidney mesangial cells; and inhibiting the growth of melanoma and breast cancer cells, etc. As has been reported, various diseases may be the results of the improper regulation of IL-6 production. Examples of the diseases reported are rheumatoid arthritis, hepatocirrhosis, psoriasis, multiple myeloma, cardiac myxoma, AIDS and other autoimmune diseases. These observations have buttressed the importance of regulating IL-6 production for the maintenance of the homeostasis of the immune system in the human body and for the treatment and prophylaxis of diseases.

Numerous approaches have been proposed to regulate the production of interleukins. For instance, proliferation of myelocytes in a patient suffering from myeloma caused by an excessive secretion of IL-6 has been suppressed by employing antibodies against IL-6 or IL-6 receptor. However, no substance or method has been reported to inhibit specifically the production of IL-6 and, therefore, there still exists a need for the discovery of specific inhibitors against the production of IL-6.

*S. japonica* Miers and *Sinomenium acutum* Rehd et Wils (Menispermaceae), which are found in the southern part of the Republic of Korea, have been used for a long time as an analgesic and anti-inflammatory agent. On the other hand, *S. tetrandra* S. Moore (Menispermaceae), which is not found in the Republic of Korea, has been used traditionally as remedies for neuralgia and arthritis, e.g. in China. Especially, the alkaloid tetrandrine has been used as an anti-inflammatory and anti-hypertensive agent. *S. tetrandra* S. Moore has been reported to have anti-phagocytic and anti-oxidizing effects, and to exhibit effectiveness in clinical and experimental silicosis models and is known to have the ability to inhibit the production of interleukin-1 and tumour necrosis factor-α which are secreted by human monocytes. Tetrandrine and its derivatives are reported to promote brain function and have been developed as an antimalarial drug and also a stimulant for hair growth.

In this study, to investigate the potent anti-inflammatory inhibitors, extracts from the root of *S. tetrandra* S. Moore were tested to suppress the production of IL-6 and inflammatory mediators. It successfully inhibited IL-6 production, and showed anti-inflammatory, anti-silicosis, and anti-cirrhotic effects in vivo and in vitro.

### Materials and methods

**Isolation of extracts of *S. tetrandra* S. Moore:**
About 4.0 kg of well dried root of *S. tetrandra* S. Moore was chopped and extracted with about 51 of methanol for 2 days. The extraction procedure was repeated three times and the combined extracts were concentrated under a reduced pressure to obtain about 224 g of the methanol extract (Extract A) with a yield of 5.6%. Two hundred grams of Extract A was partitioned with 500 ml of 90% methanol and 500 ml of *n*-hexane. The 90% methanol layer was separated and concentrated under reduced pressure to remove methanol. The residue was adjusted to pH 10 with 0.1 M NH₄OH and partitioned with 600 ml of distilled water: CHCl₃ (1:1 v/v) mixture. The CHCl₃ layer, i.e. the alkaloid fraction was then separated and concentrated under a reduced pressure to obtain about 25 g of Extract B with a yield of 0.6%. Extract C for use in a test for the treatment of silicosis was prepared as follows. One kilogram of dried root of *S. tetrandra* S. Moore was crushed into powder, sieved (60 mesh) and then suspended in distilled water in a concentration of 100 mg/ml. The resulting suspension was heated at 100°C for 6 h and filtered. The filtrate was concentrated under reduced pressure to obtain 80 g of water extract of *S. tetrandra* S. Moore (Extract C) with a yield of 8%, which was then stored at −20°C. For the purpose of preparing Extract C for the treatment of hepatocirrhosis, 1113.5 g of dried root of *S. tetrandra* S. Moore was introduced in a 31 round-bottomed flask equipped with a cooling apparatus with 21 of distilled water, and the mixture was heated at 95°C for 12 h and then filtered. The filtrate was concentrated under reduced pressure by employing a rotary vacuum evaporator (Buchi 451), frozen in a deepfreeze (Sanyo, Japan) at −84°C for 3 h, and then lyophilized for 4 h by employing a lyophilizer (Eyela, Japan) to obtain 56.55 g of powdery Extract C with a yield of 5.1%. Further, 500 g of dried root of *S. tetrandra* S. Moore was extracted with...
about 1.51 of ethanol at room temperature for 3 days. The extraction procedure was repeated three times and the combined extracts were concentrated under reduced pressure to obtain 13 g of ethanol extract of S. tetrandra S. Moore with a yield of 2.6% (Extract D).

**Cell culture:**

1. **Separation of human monocytes/macrophages.** Heparinized normal human peripheral blood was diluted with an equal amount of Hank's balanced salt solution (HBSS: Ca²⁺ and Mg²⁺ free). The diluted blood was put into a centrifuge tube containing two layers of Ficoll-Hypaque (Sigma, St Louis, MO, USA), one with a density of 1.077 and other with a density of 1.119, and then centrifuged at 700 x g for 30 min to obtain monocytes from the layer between Ficoll-Hypaque layer with a density of 1.077 and serum layer. The separated cells were washed twice with 4°C HBSS (Ca²⁺ and Mg²⁺ free) and resuspended in RPMI 1640 medium (Gibco, Grand Island, NY, USA) containing 10% foetal bovine serum (FBS, Hyclone, Logan, UT, USA). The suspensions were added to the wells of a 24-well incubation plate (Costar, Cambridge, MA, USA) and incubated at 37°C for 2 h to obtain monocytes/macrophages.

2. **Separation of alveolar macrophages.** Rat alveolar macrophages were obtained by broncho-alveolar lavage. Rat alveolar macrophages were obtained therefrom by inserting a sterilized thin tube into the bronchia and repeating three times the injection of 10 ml of RPMI 1640 medium with a 30 ml syringe. The obtained cells were centrifuged at 400 x g for 5 min, suspended in 50 ml of RPMI 1640 medium containing 10% FBS and then incubated at 37°C for 2 h to adhere to the incubation plate. The plate was washed twice with washing buffer (PBS) to remove alveolar lymphocytes (floating cells) and to obtain alveolar macrophages.

The alveolar macrophages (2 x 10⁵ cells/well) were added to the wells of a 24-well incubation plate and treated with 100 μg/ml of silica and 10 μg/ml of Extract A for 3 days. The culture was centrifuged to obtain the culture supernatants, which were then dialyzed against PBS. The activity of IL-6 was determined using an IL-6 dependent B9.55 hybridoma cell line.

3. **Separation of synoviocytes from patients with rheumatoid arthritis.** Synovial membrane tissue of a patient suffering from rheumatoid arthritis was washed three times with cool PBS and cut into small pieces, which was then suspended in Dulbecco's Modified Eagle's Medium (DMEM; Sigma, USA) containing collagenase A (5 mg/ml, BM, Indianapolis, IN, USA) and DNase type I (0.15 mg/ml, Sigma), and incubated at 37°C for 2 h in a 5% CO₂ incubator. Then, 0.5% trypsin-0.2% EDTA was added and the incubation was continued for 30 min. The digested tissue was washed twice with PBS and once with DMEM, and isolated cells were suspended in DMEM containing 10% FBS (DMEM-10% FBS) and incubated for 1 week. Thereafter, synovial adherent cells were isolated with trypsin-EDTA, washed with DMEM and then suspended in DMEM-5% FBS in a concentration of 10⁵ cells/ml.

4. **Treatment of cells with extracts of S. tetrandra S. Moore.** Extracts of S. tetrandra S. Moore were added in various concentrations to 1–5 x 10⁵/ml of cells which were obtained in the above procedures, and the cells were preincubated at 37°C for 1 h in 5% CO₂ incubator. Then, 1 ml each of silica (100 μg/ml) and RPMI 1640 medium containing 2% FBS were added and the cells were cultured under the same conditions as above for 48 h. The culture supernatant was collected and centrifuged at 1500 rpm for 10 min to remove the cells and silica. The obtained supernatant was dialyzed against PBS and filtered by 0.2 μm filtration syringe, and the filtrate was stored at −20°C.

**Assay for cytotoxicities of Extracts of S. tetrandra S. Moore.** The cytotoxicities of the extracts of S. tetrandra S. Moore were determined by the following procedures. Briefly, 5 x 10⁵ cells/ml each of monocytes and macrophages were treated with 0.1, 1 and 10 μg/ml each of Extracts A and B obtained as described above and incubated under the same conditions. In accordance with the method of Alley et al., the culture was added to the wells of the incubation plate, and 100 μg of 3-4,5-dimethylthiazol-2,5-diphenyl-tetrazolium bromide (MTT, Sigma) was added to each of the wells. After incubating at 37°C for 4 h, the culture was centrifuged to remove supernatant. One hundred each of acidified isopropanol (0.04 N HCl in isopropanol) was added to the cells in each well to elute formazan produced by the living cells, and optical density (O.D.) was determined at 540 nm by using an ELISA reader (Titertek multiskan Mcc/340).

**Cytokine assay:** TNF-α activity was measured by cytolysis of TNF-α sensitive murine fibroblast cell line, I929 cells (ATCC, CCL 1, NCTC clone 929). In brief, 3 x 10⁴ I929 cells were plated on a 96-well tissue culture plate. After 24 h incubation, media were removed and various dilutions of samples or various concentrations of recombinant human TNF-α (Genzyme, Cambridge, MA;
Stephania tetrandra suppressed IL-6 production and inflammation

specific activity $2 \times 10^7$ U/mg were added in duplicate to each well containing $1 \mu$g/ml (final concentration) of actinomycin D (Sigma) and $5\%$ FBS. After 18h incubation at $37^\circ$C, media were removed and cells were washed three times and stained with $0.5\%$ crystal violet solution containing $20\%$ methanol. After washing off the excess dye, the plates were dried and $33\%$ (v/v) acetic acid was added to each well ($100 \mu$l/well) and the optical density at $570$ nm was measured with an ELISA reader. TNF activity was expressed as U/ml from the extrapolation of the standard curve obtained using recombinant human TNF-α (Genzyme). The activity of IL-6 was determined by using an IL-6 dependent B9.55 hybridoma cell line. B9.55 cells were cultured in RPMI 1640 medium containing $10\%$ FBS with the addition of $2 \mu$g/ml of recombinant human IL-6, and the cells were washed three times with serum-free medium. The cells were suspended in RPMI 1640 medium containing $10\%$ FBS in a concentration of $5 \times 10^4$ cells/ml, and the suspension was added to the wells of a 96-well incubation plate in an amount of $100 \mu$l/well. Then the plate was incubated at $37^\circ$C under $5\%$ CO$_2$ for 68h. $[^3H]$thymidine (0.5 μCi) was added to the wells in the amount of $50 \mu$l/well and incubation continued for 4h. When the incubation was completed, the cells were collected on a glass fibre filter by using a multiple cell harvester (Inotech) and the amount of incorporated $[^3H]$thymidine was determined by a liquid scintillation counter (Beckman, Somerset, NJ, USA). IL-6 ELISA was performed using IL-6-specific monoclonal and polyclonal antibodies obtained from Genzyme (Cambridge, MA). IL-1 activity was determined using thymocyte costimulation assay as described. Briefly, thymocytes were prepared from female C3H/HeJ mice and resuspended in RPMI containing $10\%$ FBS and $2 \mu$g/ml phytohaemagglutinin. $1 \times 10^5$ cells (100 μl) were plated on a 96-well tissue culture plate and various dilutions of samples (100 μl) were added to each well. After 44h incubation, cells were labelled with 0.5 μCi/well $[^3H]$thymidine for 4h. One unit of cytokine was defined as the amount inducing the half maximal proliferation.

**IL-6 CAT assay:** The plasmid IL-6-CAT was constructed by fusing IL-6 promoter (from -1180 to +13) and the bacterial CAT transcription unit. On the day before DNA transfection, HeLa cells were plated at a density of $5 \times 10^5$ cells per 60 mm Petri dishes in DMEM supplemented with $5\%$ FBS. On day 2, 3h before transfection, fresh DMEM containing $1\%$ FBS was added and cells were transfected by the calcium phosphate-DNA co-precipitation method with a total of $8 \mu$g of IL-6-CAT DNA. After 18h, cells were washed with serum-free medium and added with fresh DMEM containing $1\%$ FBS. Then cells were further incubated for 18h in the presence of $10 \mu$g/ml of LPS plus 100 ng/ml of PMA and/or $10 \mu$g/ml of EXT.B. The cell extracts were heat-inactivated at $65^\circ$C for 10 min and centrifuged and assayed at $37^\circ$C for 2h with the equal amounts of protein (20 μg) as measured by using Bio-Rad protein assay kit. The CAT expression was detected by TLC and autoradiography.

**Collagen synthesis:** Collagen released from the fibroblast cells was measured by indirect ELISA using anti-type I collagen antibody (Southern Biotechnology). Collagen synthesized in the lung tissue of the rats was assayed by measuring the amount of hydroxyproline. To measure the amount of synthesized collagen by rat pulmonary
fibroblasts, collagen (Sigma, type I) as an internal control group was dissolved thoroughly in 1 M acetic acid containing 1 mg/ml of pepsin, and the solution was serially diluted 5-fold with coating buffer (0.05 M carbonate, pH 9.6) in a concentration ranging from 1 μg to 16 pg. The diluted solutions were added to the wells of a flat-bottomed microtiter plate (Dyntech, Cantilly, VA, USA, Immulon 2) in the amount of 100 μl/well. In addition, 1 ml of the culture supernatants of rat pulmonary fibroblast was concentrated up to 10- to 20-fold using a speedvac dryer (Savant, Hicksville, NY, USA) and dissolved in 100 μl of coating buffer (0.1 M NaHCO₃, 0.02% NaN₃; pH was adjusted to 9.6 with Na₂CO₃), and the solution was added to the wells in an amount of 100 μl/well and then incubated at 4°C overnight. The plate was washed three times with washing buffer (PBS, 0.05% Tween 20, pH 7.4), and 2% bovine serum albumin (BSA, Sigma) was added to the wells in an amount of 100 μl/well. The plate was incubated at room temperature for 2 h to block the uncoated parts. The plate was washed four times with the same buffer as above, and alkaline phosphatase-conjugated rabbit anti-goat IgG (Cappel, Dunham, NC, USA) which was 1000-fold diluted with a dilution buffer (0.05 M Tris-HCl, 1 mM MgCl₂·6H₂O, 0.15 M NaCl, 0.02% NaN₃, 1% BSA, 0.05% Tween 20, pH 8.1) was added to the wells in an amount of 100 μl/well. The plate was incubated at 37°C for 2 h and then washed three times with the same buffer. To the wells was added 100 μl/well of 2-nitrophenyl phosphate which was diluted with substrate buffer (0.05 M NaHCO₃, 10 mM MgCl₂·6H₂O, pH 9.8) in a concentration of 1 mg/ml, and the O.D. was determined using an ELISA reader at 405 nm. The amount of produced collagen was calculated from the O.D. value with reference to that of the internal control group.

Production of reactive oxygen species: The amount of H₂O₂ was determined by a microassay employing a 96-well microplate as follows. 5 × 10⁵ cells of human monocytes/macrophages were added to each well containing RPMI 1640 medium, and 25 μl of horseradish peroxidase (500 μg/ml; type II, Sigma) and 75 μl of phenol red (1 mg/ml) were added to each of the wells. Thereafter, the cells were treated with 10 μg/ml of Extract A for 1 h, stimulated with 100 μg/ml silica and then reacted at 37°C for 60 min. When the incubation was completed, 3 M NaOH was added to the wells in an amount of 25 μl/well to stop the reaction and O.D. was measured at 620 nm by using an ELISA reader. The amount of H₂O₂ was determined by employing a standard curve prepared using the diluted standard H₂O₂ (Sigma).

For the purpose of measuring the amount of produced O₂⁻, monocytes/macrophages suspended in RPMI 1640 medium in a concentration of 1 × 10⁶ cells/800 μl was added to the wells of a 24-well plate, and 10 μg/ml of superoxide dismutase (SOD, Sigma) was added to the empty wells. The plate was stored at 37°C for 2 min, and cytochrome C (3 mg/ml, Sigma) was added to the wells in a concentration of 100 μl/well. The cells were treated with 10 μg/ml of Extract A for 1 h, and stimulated at 37°C for 20 min by adding 100 μg/ml silica. The reaction was terminated by adding 1 mM N-ethylmaleimide (Sigma) to the wells and the culture was centrifuged at 1 600 × g for 10 min to obtain the supernatants. The change of color caused by the reduction of cytochrome C was measured at 550 nm using an UV-visible spectrophotometer (Kontron Instrument, Milan, Italy). The amount of produced O₂⁻ was represented by the concentration of SOD which can suppress the reduction of cytochrome C in 1 × 10⁶ cells for 20 min, by employing the extinction coefficient of cytochrome C (E₅₅₀nm = 1.83 × 10⁴ mM⁻¹ cm⁻¹).

Experimental silicosis and cirrhosis model: To induce the experimental hepatocirrhosis in 4-week aged male Sprague-Dawley rats, 0.1 ml/100 g of body weight of CCl₄ solution (50% CCl₄ + 50% corn oil) was injected intraperitoneally to the rats twice a week, and 0.2 ml each of Extract A, B, C or D was administered orally at the time of the injections of CCl₄ twice a week. After 13 weeks, each of the rats was anaesthetized with ether and blood samples were obtained from the heart to determine the levels of serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT).

For the pathohistologic examination of the livers separated from the rats, the liver was fixed in 10% aqueous solution of neutral formalin and then embedded in paraffin. The embedded tissue was sectioned into 5 mm slices, stained with haematoxylin eosin and Masson's trichrome, and then observed under the microscope.

Results

Cytotoxicity of extracts of S. tetrandra S. Moore: The cytotoxicity of the extracts of S. tetrandra S. Moore were determined as described Materials and Methods. Figure 1 shows the relative values of optical density of the sample with respect to the concentration of Extract A or B when the optical density of the control group which was not treated with Extract A or B is regarded as.
Stephania tetrandra suppressed IL-6 production and inflammation

100%. The samples treated with Extract A show no difference from the control group until the concentration of Extract A reaches 10 μg/ml, and the samples treated with Extract B show similar results. Therefore, it indicated that Extracts A and B had no cytotoxicity at concentrations lower than 10 μg/ml, therefore, hereinafter, all the tests were carried out within this concentration. Both Extracts A and B showed cytotoxicity at the concentration of 100 μg/ml. *In vivo* oral treatment of Extracts C and D showed no apparent toxicity to the rats (death, loss of weight, etc.) when it was administered twice a week for 17 weeks (data not shown).

Inhibition of IL-6 production by extracts of *S. tetrandra* S. Moore: Human monocytes/macrophages were incubated with 0.1 to 10 μg/ml of Extract A or B for 1 h and treated with 100 μg/ml of silica for 48 h. The culture was centrifuged to obtain the culture supernatants, which were then dialysed against PBS. IL-6 production was measured by IL-6 bioassay using B9.55 cell line. Figure 2A shows the relative values of the...
amount of incorporated $[^3]$H]thymidine with respect to the concentration of Extract A or B compared with those of the control group. IL-6 production by monocyte/macrophage was inhibited by Extract A or B in a dose-dependent mode, and it was inhibited by 50% with 10 μg/ml of Extract A or B. As shown in Fig. 2B, it was observed that the IL-6 production by rat alveolar macrophages was also inhibited by Extract A. As blank controls for possible residual effects of compounds and silica on bioassay, the same concentrations of compounds and silica were mixed with fresh media and dialysed as the culture supernatants were prepared. These blank controls had no effects on bioassay (data not shown). The results of IL-6 bioassay were further confirmed by IL-6 ELISA (Fig. 2C). In this case, cells were treated with 10 μg/ml pokeweed mitogen (PWM) and 10 μg/ml extracts. Extract A and B showed dramatic inhibitory effects on IL-6 production. Next, the effects of *S. tetrandra* S. Moore on IL-6 production *in vivo* were analysed.

In the experimental silicosis model, IL-6 activities in the serum (Fig. 2D) and in the culture supernatants of pulmonary fibroblasts isolated from the rats treated with compounds or anti-murine IL-6 monoclonal antibody (Fig. 2E) were determined as described in Materials and Methods. IL-6 activity was inhibited by injecting anti-IL-6 antibody as expected. And its activity was also inhibited by Extract C in both cases, indicating that the extracts of *S. tetrandra* S. Moore exhibited the inhibitory effects on IL-6 production in the animal silicosis models.

**Suppression of IL-6 gene expression by extracts of* S. tetrandra* S. Moore:** In addition, to confirm the effects of the extracts of *S. tetrandra* S. Moore on the IL-6 gene expression, the effect of Extract B on synoviocytes which were obtained from the patients with rheumatoid arthritis caused by the overproduction of IL-6 was analysed. As can be seen in Fig. 3A, the expression of constantly expressed adenine phosphoribosyl transferase (APRT) RNA was not influenced by Extract B, while IL-6 RNA expression was significantly inhibited by 10 μg/ml of the Extract B. When IL-6-CAT construct was used to see the effects of Extract B on IL-6 promoter activity, the IL-6 promoter activity induced by LPS plus PMA was suppressed about 60% by 10 μg/ml of the Extract B. However, acanthoic acid (A), another natural product which had no effect on IL-6 production, did not inhibit the IL-6 expression (Fig. 3B, C). These results indicated that the extracts of *S. tetrandra* S. Moore suppressed IL-6 production at the transcriptional level, and further studies are required to know the exact mechanism of its action.
Stephania tetrandra suppressed IL-6 production and inflammation

Inhibition of silicosis by extracts of S. tetrandra S. Moore: IL-6 is known as a cytokine which causes fibrogenesis and induces collagen synthesis in rat fibroblasts. Based on the observation of the inhibitory effects on the IL-6 production, their inhibitory effect on the collagen synthesis in rat pulmonary fibroblasts and pulmonary tissues was determined. As a result, it was observed that the amount of synthesized collagen was significantly decreased in the culture supernatants of rat pulmonary fibroblasts which were treated with 10 μg/ml of Extract A compared with the control (Fig. 4A). Furthermore, in vivo effects of S. tetrandra S. Moore (Extract C) on the collagen synthesis in rat pulmonary tissues was tested by injecting 500 mg of silica and 40 mg of Extract C orally into the rats twice a week for 17 weeks, and then the amount of hydroxyproline was measured as described in Materials and Methods. In Fig. 4B, the amount of collagen synthesized by rat pulmonary tissues from the rats treated with silica only (si) or treated with silica and dimethylsulphoxide (si+DMSO) increased about twice compared with the control, while the amount of synthesized collagen decreased by 50% in rat pulmonary tissue treated with silica, DMSO and Extract C (si+EXT.C). These results showed that the extracts of S. tetrandra S. Moore had anti-fibrogenic activity in vitro and in vivo.

Inflammatory responses are known as a cascade reaction comprising the secretion of various cytokines such as IL-1, IL-6, and TNF-α.

**Fig. 4.** Inhibition of collagen synthesis by extracts of S. tetrandra S. Moore. (A) Primary rat lung fibroblasts (5 x 10^5 cells/well) were preincubated with 10 μg/ml Extract A for 1 h and stimulated with 100 μg/ml silica. After 48 h incubation, the culture supernatants were assayed for collagen production by ELISA using anti-collagen type I antibody. (B) The experimental silicosis was induced as described in Materials and Methods. Then, Extract C (40 mg/injection) was orally injected into the silicosis rat twice per week for 17 weeks. The lung tissue (0.1 g) was hydrolyzed and assayed for collagen content by measuring hydroxyproline. Data represent the percentages of control (normal lung).

**Fig. 5.** Inhibition of production of reactive oxygen species by extract of S. tetrandra S. Moore. For hydrogen peroxide analysis, human monocytes/macrophages (5 x 10^6 cells/ml) pretreated with 10 μg/ml Extract A for 1 h were stimulated with 100 μg/ml silica for 1 h in the presence of horseradish peroxidase and phenol red. For superoxide anion analysis, human monocytes/macrophages (1 x 10^6 cells/800 μl) pretreated with 10 μg/ml Extract A were stimulated with 100 μg/ml silica for 20 min in the presence of cytochrome C. □, superoxide anion; ■, hydrogen peroxide.
from immune cells stimulated by various stimulants; production of phospholipase A₂, lysosomal enzyme, reactive oxygen species, etc. by other immune cells stimulated by various cytokines; and damage of tissues induced by the inflammatory mediators. The ability of the extracts of S. tetrandra S. Moore to block the inflammatory reactions was tested by measuring their inhibitory activity to the production of reactive oxygen species such as H₂O₂ and O₂⁻. As can be seen from Fig. 5, the amounts of H₂O₂ and O₂⁻ decreased significantly in the silica-stimulated and Extract A-treated monocytes/macrophage (si + EXT.A) in contrast with the control group treated with only silica (si + MED).

Inhibition of hepatocirrhosis by extracts of S. tetrandra S. Moore: Cirrhosis is another fibrotic disease in the liver. Anti-inflammatory effects of S. tetrandra S. Moore were analysed in the experimental cirrhosis model. When compared with the blood sample obtained from the rats treated with CCl₄, DMSO, and PBS, sGOT values of the blood samples obtained from the rats treated with Extract A or C did not decrease, but those of samples obtained from the rat treated with Extract D or B decreased by 20% and 40%, respectively (Fig. 6A). Further, sGPT in the blood samples obtained from the rats treated with Extract B decreased more than 60% (Fig. 6B).

In the liver of the rats administered with CCl₄ only (Fig. 7B), the nodule formation of hepatic lobules with the thickened fibrous bands was remarkable compared with the normal liver (Fig. 7A). In the liver of the rats administered with CCl₄ and Extract B (Fig. 7D), the fibrous bands surrounding the nodule of hepatic lobule were thinner than those of the liver obtained from the rats treated with CCl₄ only, and many nodules were incomplete. Also, the regenerative change of hepatic cells decreased compared with that of the liver obtained from the rats treated with CCl₄ only. In the liver of the rats administered with CCl₄ and Extract A (Fig. 7C), the suppressive effect on the hepatocirrhosis was not dominant as seen in the case of Extract B.

Discussion

Inflammation is a localized or systemic response induced by infection or injury to tissues. Right after exposure to injurious agents, monocytes and macrophages synthesize and release a variety of inflammatory mediators such as oxygen free radicals, proteases, platelet-activating factors, and proinflammatory cytokines. They are major inflammatory mediators that modulate fibroblast proliferation, neutrophil function, and collagen synthesis. Once macrophages infiltrated into inflammatory sites, NADPH-oxidase in the membrane is activated to produce the oxygen radicals. The oxygen radicals are then reduced to superoxide anion by receiving an electron from NADPH, and then dismutated to hydrogen peroxide. These reaction oxygen radicals then damage the tissues in the inflammatory sites.
Stephania tetrandra suppressed IL-6 production and inflammation

**FIG. 7.** Extracts of *S. tetrandra* S. Moore suppressed the experimental cirrhosis. 40 mg each of Extract A, B was injected into cirrhotic rats for 13 weeks. The liver was fixed, stained with Masson's trichrome stain for histological analysis. (A) normal liver, (B) CCl4, (C) CCl4 and Extract A, (D) CCl4 and Extract B. Data shown the mean ± SD of three different determinants.

Therefore, an excessive quantity of these cytokines and free radicals caused tissue destruction in the inflammatory sites and they are involved in many immune diseases and inflammatory diseases. To inhibit their action, several protein antagonists such as IL-1ra, monoclonal antibodies to proinflammatory cytokines, and these cytokine receptors have been developed to block acute and chronic inflammation. But these protein antagonists have some limitations such as stability and delivery to be used clinically as anti-inflammatory agents.

Two major aspects of the proliferation of fibroblasts and the production of collagen are the hallmarks of fibrosis. IL-6 has been known to be involved in this process in connection with other fibrogenic cytokines. To modulate IL-6 production, *S. tetrandra* S. Moore, known as anti-inflammatory agent, was tested in different inflammatory systems. First, several aspects of IL-6 in chronic inflammation including silicosis, rheumatoid arthritis, and liver cirrhosis were evaluated. Significantly elevated levels of IL-6 activity were observed in silica-treated monocytes/macrophages.
phages, and in the sera of CCl4-treated rats and the patients with rheumatoid arthritis, indicating that IL-6 is a key element in an inflammatory cytokine network. The culture supernatants of human monocytes/macrophages treated with S. tetrandra S. Moore contained far less IL-6 activity compared with those treated with silica alone. In addition, it suppressed the IL-6 gene expression, collagen synthesis, and the production of reactive oxygen from several inflammatory cells, suggesting that it had potent anti-fibrogenic effects. But it cannot be ruled out that S. tetrandra S. Moore may regulate the production of other proinflammatory cytokines. Actually, Extract B of S. tetrandra S. Moore showed the inhibitory effects on IL-1 production (29.1% and 45% inhibition at the concentration of 1 μg/ml and 10 μg/ml, respectively) and on TNF-α production (5.2% and 18.6% inhibition at the concentration of 1 μg/ml and 10 μg/ml, respectively). The further fractionation of the extracts to identify the effective components inhibiting each cytokine production is now in progress.

To evaluate the in vivo effects of S. tetrandra S. Moore, two different experimental models, in which IL-6 is known to be involved, were tested. Silicosis is a chronic lung inflammation. By the exposure to stimuli, alveolar macrophages are activated and secrete many fibrogenic mediators. S. tetrandra S. Moore strongly suppressed the experimental silicosis induced by silica treatment. It reduced the collagen production, and granuloma formation and fibrosis in the lung.

Hepatocirrhosis is characterized by the fibrogenesis of the whole liver, complete disruption of liver parenchyma by the fibrous septa, and formation of regenerative nodules. It is derived mostly from a chronic hepatitis or chronic alcoholism, however, the precise causes are unknown. We previously reported that in vivo administration of IL-6 could induce the early stage of liver cirrhosis. In a hepatocirrhosis patient, the amount of cytokines, e.g. IL-6 which is involved in the inflammation and fibrogenesis, is in an increased state. Based on its effects on IL-6 production, these inhibitory effects in vivo might be due to reduction of IL-6 and/or other inflammatory mediators induced by IL-6 such as reactive oxygen free radicals.

Various root extracts of S. tetrandra S. Moore which inhibit the production of interleukin-6, can be used for the preparation thereof and pharmaceutical compositions comprising extracts which are effective for the treatment of immune diseases caused by the overproduction of interleukin-6. Each of Extracts A, B, C and D exhibited an anti-inflammatory effect, inhibited the synthesis of collagen and the production of the reactive oxygen species and reduced GOT and GPT level in the serum. Therefore, they can be employed alone or in combination with each other in a pharmaceutical composition for the treatment of such immune diseases caused by an excessive production of IL-6 as rheumatoid arthritis, hepatocirrhosis, psoriasis, multiple myeloma, cardiac myxoma, and silicosis. These extracts seemed to have the similar effects on IL-6 production, but they showed some different effects on experimental animal models. The Extract B was most effective in suppressing serum GOT and GPT level, and hepatic cirrhosis. Preferably the Extract B may be applied for the treatment of inflammatory disease, arthritis and autoimmune hepatocirrhosis, but the subsequent studies are required to identify the active compounds as mentioned above.

In summary, significantly elevated levels of IL-6 activity and concentration were observed in silica-treated human monocytes/macrophages, CCl4 or silica-treated rats, and the patients with rheumatoid arthritis. In addition, IL-6 itself augmented fibrogenic events such as fibroblast or synoviocyte proliferation, and collagen synthesis. S. tetrandra S. Moore possesses the ability to inhibit the production of IL-6 and inflammatory mediators in a concentration-dependent fashion. It was also effective in experimental silicosis and cirrhosis models. Considering its effects on cytokine regulation and in vivo effects, it can be used as an anti-fibrosis agent in the treatment of many inflammatory diseases. Further biological and immunological analysis of its isolated compounds can lead to the development of more specific anti-inflammatory therapeutics for the treatment of various immune diseases caused by an excessive production of IL-6 and other inflammatory mediators.

References
1. Kovacs EC. Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. *Immunol Today* 1991; 12: 17–23.
2. Wahl SM, Wahl LM. Modulation of fibroblast growth and function by monokines and lymphokines. *Lymphokines 1981*; 2: 179–200.
3. Shalaby MR, Aggarwal BB, Rinderknecht E, Svedersky LP, Fridde BS, Palladino MA. Activation of human polymorphonuclear neutrophil functions by interferon-γ and tumor necrosis factors. *J Immunol* 1985; 135: 2069–2073.
4. Schmidt JJ, Mitzel SC, Cohen D, Green I. Interleukin-1, a potential regulator of fibroblast proliferation. *J Immunol* 1982; 128: 2177–2182.
5. Davis GS. pathogenesis of silicosis: current concepts and hypothesis. *Lung* 1996; 164: 129–154.
6. Kovacs EC. Fibrogenic cytokines: the roles of immune mediators in the development of scar tissue. *Immunol Today* 1991; 12: 17–23.
7. Kumar RK. Quantitative immunohistological assessment of lymphocyte populations in the pulmonary inflammatory response to intranasal silica. *Am J Pathol* 1989; 135: 605–614.
8. Castilla A, Prieto J, Farusto N. Transforming growth factor-β1 and α in chronic liver disease. *N Engl J Med* 1991; 324: 935–940.
9. Czaja MJ, Weitner PR, Hander KG, Giambra MA, Wind R, Biempića I, Zeno MA. *In vitro* and *in vivo* association of transforming growth factor-β1 with hepatic fibrosis. *J Cell Biol* 1989; 108: 2477–2482.
10. Hirano T, Aldia S, Tago T, Kishimoto T. Biological and clinical aspects of interleukin-6. *Immunol Today* 1990; 11: 443–449.
Stephania tetandra suppressed IL-6 production and inflammation

11. Maruguchi A, Kishimoto T, Miki Y, Kunitani T, Kaida T, Yoshizaki K, Yamamura S. T Cell-stimulating factor (TBF) induced IgG secretion in a human B blastsoid cell line and demonstration of receptors for TNF. *J Immunol* 1991; 147: 412–416.

12. Takeguchi H, Itoh T, Totsuya T, Yussaw M, Tadao M, Shinichi K, Kosel J, Kishi M, Akihito I, Susumu T, Fumio S, Hiroshi M, Toshiyuki T, Tadatsugu T, Tadatsugu K. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. *Nature* 1986; 324: 73–76.

13. Stack VJ, Casapasi S, Yank A, Uytenhove K, Cudie PG, Rubira MD, Stegeman RJ. Purification and N-terminal amino acid sequence of a T cell-derived lymphokine with growth factor activity for B cell hybridomas. *Proc Natl Acad Sci USA* 1986; 83: 9679–9683.

14. Kolte K, Nakahara T, Takagi M, Kobayashi T, Ishiguro T, Naga- numa K, Okuno A, Akita Y, Akabane T. Synergism of BSF-2/interleukin-6 and interleukin-3 on development of multipotential hematopoietic progenitors in serum-free culture. *J Exp Med* 1988; 168: 879–890.

15. Lom J, Jank F, Kobayashi P, Tison JP, Tada T, Kishimoto T, Carson DA. B cell stimulatory factor 2/interleukin-6 is a costimulant for human T lymphocytes and T lymphocytes. *J Exp Med* 1988; 167: 1253–1258.

16. Geiger T, Andus T, Kapproth J, Hinaro T, Kishimoto T, Heinrich PC. Induction of rat acute-phase proteins by interleukin-6 in vivo. *Eur J Immunol* 1988; 18: 717–721.

17. Sato T, Nakamura S, Taga T, Motoda T, Hinaro T, Kishimoto T, Kazuo Y. Induction of neuronal differentiation in PC12 cells by a B cell stimulatory factor 2. *Cell Biol* 1988; 6: 3545–3559.

18. Hinaro T, Motoda T, Tunner M, Mitsuoka N, Buchanan G, Targ B, Sato K, Shizuma M, Maini R, Feldmann M, Kishimoto T. Excessive production of interleukin-1 and interferon-gamma in patients with ulcerative colitis in serum-free culture. *Eur J Immunol* 1988; 18: 1797–1801.

19. Dierdre J, Content J, Denys C, Vanderdonkse P, Schandone I, Wyman J, Dupino J, Kapproth J, Buxo R, Gruarin D, Tisher JC, May LT, Uppen RE. Sehgal PB, Gotlieb AB. Interleukin-6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. *Proc Natl Acad Sci USA* 1989; 86: 6367–6371.

20. Busilale R, Yano Y, Zhang XG, Kent B, Bumon levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. *J Clin Immunol* 1989; 9: 206–211.

21. Jardain M, Busilale R, Segun J, Zhang XG, Chapin PA, Klein B. Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. *Arthritis Rheum* 1990; 33: 598–602.

22. Miles SA, Resit AR, Saliar-Gonzalez MF, Vandez-Mezon M, Stevens RH, Logan DM, Mitsuaya RT, Tapa T, Hinaro T, Kishimoto T, Martinez-Maza O. AIDS kaposi sarcoma-derived cells produce and respond to interleukin-6. *Proc Natl Acad Sci USA* 1990; 87: 6068–6072.

23. Suzuki H, Yamanaka K, Sato Y, Gotshuka A, Hasegawa A, Obusui Y, Taga T, Kishimoto T. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo. *Eur J Immunol* 1991; 22: 1899–1903.

24. Secov WK, Ferrante A, Goh DB, Chalmers AH, Li SY, Thong YH. In vitro immunosuppressive properties of the plant alkaloid tetrandrine. *Int Arch Allergy Appl Immunol* 1988; 85: 410–415.

25. Secov WK, Ferrante A, Syngling L, Thong YH. Antiphlogistic and anti-oxidant properties of the plant alkaloid tetrandrine. *Int Arch Allergy Appl Immunol* 1988; 85: 404–409.

26. Secov WK, Ferrante A, Syngling L, Thong YH. Suppression of human monocyte interleukin-1 production by the plant alkaloid tetrandrine. *Clin Exp Immunol* 1989; 75: 47–51.

27. Ferrante A, Secov WK, Rowan-Kelly B, Thong YH. Tetrandrine, a plant alkaloid, inhibits the production of tumor necrosis factor-alpha (cachectin) by human monocytes. *Clin Exp Immunol* 1990: 80: 235–235.

28. Castranova V, Kang JH, Moore MD, Palles WH, Frances DJ, Schwenger-Berry D. Inhibition of stimulant-induced activation of phagocytic cells with tetrandrine. *J Leuk Biol* 1991; 50: 412–422.

29. Alley MC, Scodiero DA, Munk A, Hussey ML, Czerwinski MJ, Fine DL, Abbott B, Mayo JOG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrasodium assay. *Cancer Res* 1988; 48: 589–601.

30. Ray A, Tater SB, May LT, Sehgal PB. Activation of the human interleukin-6/interleukin-6 receptor/interleukin-6 receptor-6/5 promoter by cytokines, viruses, and second messenger agonists. *Proc Natl Acad Sci USA* 1988; 85: 6701–6705.

31. Huaier G, Malovec J, Nafzolin P. Monitoring of collagen and collagen fragments in chromatography of protein mixture. *Anal Biochem* 1988; 105: 424–429.

32. Nakasuka A, Yagi P, Inuerep P, Hsia CC, Mansend R, Thorgersen SS. Cellular distribution of transforming growth factor-beta 1 and procollagen type Ibeta and anti-fibrotic properties of the plant alkaloid tetrandrine. *J Clin Invest* 1990; 85: 1833–1843.

33. Kang HS, Kim YH, Lee CS, Lee JJ, Choi I, Pyun KH. Suppression of interleukin-1 secretion and tumor necrosis factor production by acidic acid, (-)-pimara-9(11),15-dien-19-oic acid, and its anti-fibrotic effects in vivo. *Cell Immunol* 1995 (in press).

34. Kang HS, Choi I, Pyun KH. Modulation of TNF-alpha and IL-6 production in LNCaP cells. *Eur J Immunol* 1996 (in press).

35. Chao I, Kan Y, Pyun KH. Expression of IL-6 and TNF-alpha in the pathogenesis of silicosis. *Kor J BMC* 1994; 4: 97–109.

36. Pruzanski W, Vadas P. Phospholipase A2 mediated between proximal and distal effector of inflammation. *Inflammation Today* 1991; 12: 143–146.

37. Choi I, Kang HS, Yang K, Pyun KH. IL-6 induces hepatic inflammation and collagen synthesis in vivo. *Clin Exp Immunol* 1994; 95: 530–535.

ACKNOWLEDGEMENT. This work was supported by the grants (HAN project HS020M and GG033S) from MOST, Republic of Korea.

**Received 28 May 1996; accepted 12 June 1996**

Mediators of Inflammation Vol 5 1996 291